Oruka Therapeutics (ORKA) Current Assets (2010 - 2026)

Oruka Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $395.2 million for Q1 2026.

• On a quarterly basis, Current Assets rose 12.26% year-over-year to $395.2 million in Q1 2026; TTM through Mar 2026 was $395.2 million, a 12.26% increase from a year earlier, with the FY2025 full-year figure at $343.9 million, down 8.76% from the prior year.
• Current Assets rose to $395.2 million in Q1 2026 per ORKA's latest filing, from $343.9 million in the prior quarter.
• Across five years, Current Assets topped out at $412.9 million in Q3 2024 and bottomed at $33.8 million in Q2 2024.
• The 5-year median for Current Assets is $47.7 million (2022), against an average of $175.5 million.
• Across the five-year window, Current Assets fell 26.47% in 2022 and soared 961.78% in 2024, its largest moves.
• Year by year, Current Assets stood at $42.7 million in 2022, then slipped by 11.96% to $37.6 million in 2023, then soared by 902.52% to $376.9 million in 2024, then slipped by 8.76% to $343.9 million in 2025, then climbed by 14.95% to $395.2 million in 2026.
• Per Business Quant, the three latest ORKA Current Assets figures stand at $395.2 million (Q1 2026), $343.9 million (Q4 2025), and $355.2 million (Q3 2025).